6.47
전일 마감가:
$6.36
열려 있는:
$6.42
하루 거래량:
1.35M
Relative Volume:
1.04
시가총액:
$560.14M
수익:
-
순이익/손실:
$-168.09M
주가수익비율:
-2.9816
EPS:
-2.17
순현금흐름:
$-138.01M
1주 성능:
+1.89%
1개월 성능:
+10.60%
6개월 성능:
-12.45%
1년 성능:
-69.12%
Kura Oncology Inc Stock (KURA) Company Profile
명칭
Kura Oncology Inc
전화
(858) 500-8800
주소
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
KURA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
KURA
Kura Oncology Inc
|
6.47 | 549.75M | 0 | -168.09M | -138.01M | -2.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
2024-10-24 | 개시 | UBS | Buy |
2024-10-14 | 다운그레이드 | Stifel | Buy → Hold |
2023-12-22 | 개시 | Mizuho | Buy |
2023-08-11 | 개시 | BofA Securities | Buy |
2023-07-27 | 개시 | Scotiabank | Sector Perform |
2023-05-17 | 개시 | BTIG Research | Buy |
2023-01-31 | 개시 | Stifel | Buy |
2022-07-12 | 개시 | Cantor Fitzgerald | Overweight |
2022-02-15 | 개시 | Jefferies | Buy |
2021-05-05 | 재개 | Credit Suisse | Outperform |
2021-04-26 | 재개 | Credit Suisse | Outperform |
2020-12-07 | 재확인 | H.C. Wainwright | Buy |
2020-12-03 | 개시 | Stifel | Buy |
2020-11-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2020-07-07 | 개시 | Credit Suisse | Outperform |
2020-05-05 | 개시 | Barclays | Overweight |
2019-07-18 | 개시 | Deutsche Bank | Buy |
2018-11-09 | 개시 | Piper Jaffray | Overweight |
2018-08-01 | 개시 | H.C. Wainwright | Buy |
2016-10-13 | 재개 | Leerink Partners | Outperform |
2016-01-22 | 개시 | JMP Securities | Mkt Outperform |
2015-12-30 | 개시 | Oppenheimer | Outperform |
2015-12-16 | 개시 | Citigroup | Buy |
모두보기
Kura Oncology Inc 주식(KURA)의 최신 뉴스
What drives Kura Oncology Inc. stock priceOutstanding yields - Autocar Professional
What analysts say about Kura Oncology Inc. stockSignificant capital appreciation - Autocar Professional
Is Kura Oncology Inc. a good long term investmentExplosive portfolio gains - jammulinksnews.com
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Kura Oncology Inc. Stock Analysis and ForecastDouble-digit growth - Jammu Links News
Why Kura Oncology Inc. stock attracts strong analyst attentionFree AI-Driven Trading Strategies - Newser
Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight - Yahoo Finance
How Kura Oncology Inc. stock performs during market volatilityFree Access to Group - Newser
What makes Kura Oncology Inc. stock price move sharplyHigh Reward Risk Balanced Trading - Newser
Health Check: How Prudently Does Kura Oncology (NASDAQ:KURA) Use Debt? - simplywall.st
Wealth Enhancement Advisory Services LLC Takes $139,000 Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology shares rise 3.34% after-hours following inducement grants to new employees. - AInvest
Kura Oncology's Ziftomenib: A Near-Term FDA Catalyst and a Paradigm Shift for AML Patients - AInvest
Kura Oncology Partners with Kyowa Kirin for Ziftomenib - TipRanks
Kura Oncology and Kyowa Kirin enter agreement to co-promote leukemia drug in US - Investing.com
Kura Oncology and Kyowa Kirin enter agreement to co-promote leukemia drug in US By Investing.com - Investing.com South Africa
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 3000E Value Index - MarketScreener
Kura Oncology (NASDAQ:KURA) Given Overweight Rating at Cantor Fitzgerald - Defense World
KURA: Cantor Fitzgerald Reiterates Overweight Rating | KURA Stoc - GuruFocus
Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by Rhumbline Advisers - Defense World
KURA: Wedbush Reiterates 'Outperform' Rating with $36 Price Target | KURA Stock News - GuruFocus
Transcript : Kura Oncology, Inc.Special Call - MarketScreener
Kura Oncology Announces Positive Phase 1a/1b Trial Results - TipRanks
Long Term Trading Analysis for (KURA) - news.stocktradersdaily.com
Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN
Pallas Capital Advisors LLC Invests $66,000 in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Harbor Capital Advisors Inc. - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook - Investing.com Australia
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook By Investing.com - Investing.com South Africa
KURA's Ziftomenib Shows Promising Results in AML Clinical Trial - GuruFocus
Kura Oncology reports positive data for AML treatment ziftomenib By Investing.com - Investing.com South Africa
Is the Options Market Predicting a Spike in Kura Oncology Stock? - The Globe and Mail
Kura Oncology (KURA) Shows Promising Results for AML Therapy - GuruFocus
Kura Oncology Says Ziftomenib Study Achieves Complete Remission in Acute Myeloid Leukemia - MarketScreener
Kura Oncology stock rises on leukemia drug data (KURA:NASDAQ) - Seeking Alpha
Is The Options Market Predicting A Spike In Kura Oncology Stock? - Barchart.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combinatio - GuruFocus
Kura Oncology’s SWOT analysis: ziftomenib stock potential in AML treatment By Investing.com - Investing.com Canada
Kura Oncology and Kyowa Kirin Report Strong Results from KOMET-007 Trial of Ziftomenib in Newly Diagnosed AML Patients - Nasdaq
Kura Oncology reports positive data for AML treatment ziftomenib - Investing.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly ... - Enidnews.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress - Yahoo Finance
Kura Oncology’s SWOT analysis: ziftomenib stock potential in AML treatment - Investing.com
Kura Oncology Inc (KURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):